Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

CTLA-4 Control over Foxp3 + Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206

Plat-E: an efficient and stable system for transient packaging of retroviruses

MORITA, S., Kojima, T., & Kitamura, T. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301206 · Cited by 1,660

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967

CD28 and CTLA-4 coreceptor expression and signal transduction

Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898

Foxp3 + natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation

Onishi, Y., Fehervari, Z. T., Yamaguchi, T., & Sakaguchi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711106105 · Cited by 754

B cells acquire antigen from target cells after synapse formation

Batista, F. D., Iber, D., & Neuberger, M. S. (2001) · Nature · doi:10.1038/35078099 · Cited by 629

A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION

Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 526

How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation

Abraham, R. S. (2020) · Hematology · doi:10.1182/hematology.2020000173 · Cited by 24

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma

Chen, X., Wu, W., Wei, W., & Zou, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869488 · Cited by 24

Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer

Minohara, K., Imai, M., Matoba, T., Wing, J. B., Shime, H., Odanaka, M., Uraki, R., Kawakita, D., Toyama, T., Takahashi, S., et al. (2022) · Cancer Science · doi:10.1111/cas.15698 · Cited by 23

The potential for Treg-enhancing therapies in transplantation

Steiner, R., & Pilat, N. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac118 · Cited by 25

Lymphoid Tissue Inducer Cells: Pivotal Cells in the Evolution of CD4 Immunity and Tolerance?

Lane, P. J. L., Gaspal, F., McConnell, F. M., Withers, D. R., & Anderson, G. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00024 · Cited by 24

Role of Regulatory T Cells (Treg) and the Treg Effector Molecule Fibrinogen-like Protein 2 in Alloimmunity and Autoimmunity

Chruscinski, A. J., Sadozai, H., Rojas-Luengas, V., Bartczak, A. M., Khattar, R., Selzner, N., & Levy, G. A. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10209 · Cited by 24

Orchestrating Lymphocyte Polarity in Cognate Immune Cell–Cell Interactions

Bustos‐Morán, E., Blas‐Rus, N., Martin-Cofreces, N. B., & Sánchez‐Madrid, F. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.06.004 · Cited by 26

Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model

Field, C. S., Hunn, M. K., Ferguson, P. M., Ruedl, C., Ancelet, L. R., & Hermans, I. F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1376154 · Cited by 22

Tumor Necrosis Factor Receptor Superfamily in T Cell Priming and Effector Function

Muller, J., Baeyens, A., & Dustin, M. L. (2018) · Advances in immunology · doi:10.1016/bs.ai.2018.08.001 · Cited by 24

A novel system to map protein interactions reveals evolutionarily conserved immune evasion pathways on transmissible cancers

Flies, A. S., Darby, J. M., Lennard, P. R., Murphy, P. R., Ong, C. E. B., Pinfold, T. L., Luca, A. D., Lyons, A. B., Woods, G. M., & Patchett, A. L. (2020) · Science Advances · doi:10.1126/sciadv.aba5031 · Cited by 24

Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression

Armitage, J. D., Newnes, H. V., McDonnell, A. M., Bosco, A., & Waithman, J. C. (2021) · Cells · doi:10.3390/cells10010056 · Cited by 26

Regulatory T-cell dysfunction and its implication for cell therapy

Valentini, N., Cier, C. J. R., & Lamarche, C. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad051 · Cited by 24

Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma – a multicenter phase 2 trial (EPOC1802)

Bando, H., Kumagai, S., Kotani, D., Mishima, S., Irie, T., Itahashi, K., Tanaka, Y., Habu, T., Fukaya, S., Kondo, M., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00918-1 · Cited by 24

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Yang, Y. P., Yao, X., Wang, Q., Yang, M., Li, R., Qin, J., Zhuang, J., & Sun, C. (2026) · Advanced Science · doi:10.1002/advs.202520634 · Cited by 27

Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists

Callahan, M. K., & Wolchok, J. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.008 · Cited by 23

1,25(OH)2D3 Promotes the Efficacy of CD28 Costimulation Blockade by Abatacept

Gardner, D. H., Jeffery, L. E., Soskic, B., Briggs, Z., Hou, T. Z., Raza, K., & Sansom, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500306 · Cited by 23

Pediatric Patients With Steroid-Sensitive Nephrotic Syndrome Have Higher Expression of T Regulatory Lymphocytes in Comparison to Steroid-Resistant Disease

Guimarães, F. T. L., Ferreira, R. N., de Melo, G. E. B. A., Rocha‐Vieira, E., Pereira, W. D. F., Pinheiro, S. V. B., de Miranda, A. S., & Silva, A. C. S. E. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00114 · Cited by 23

Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors

Ogawa, S., & Abe, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_4 · Cited by 22

Differential trafficking of ligands trogocytosed via CD28 versus CTLA4 promotes collective cellular control of co-stimulation

Zenke, S., Sica, M. P., Steinberg, F., Braun, J. M., Zink, A., Gavrilov, A., Hilger, A., Arra, A., Brunner-Weinzierl, M. C., Elling, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34156-1 · Cited by 25

Setting a stage: Inflammation during preeclampsia and postpartum

Herrock, O., Deer, E. M., & LaMarca, B. B. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1130116 · Cited by 28

A key driver to promote HCC: Cellular crosstalk in tumor microenvironment

Liu, P., Lingyu, K., Liu, Y., Li, G., Xie, J., & Lu, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135122 · Cited by 26

Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future

Pan, M., Zhao, H., Jin, R., Leung, P. S. C., & Shuai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156212 · Cited by 24

Dead on Arrival: Understanding the Failure of CTLA4-Immunoglobulin Therapy in Inflammatory Bowel Disease

Mayer, L., Kaser, A., & Blumberg, R. S. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.015 · Cited by 24

Gene and cell therapy for pancreatic cancer

Singh, H. M., Ungerechts, G., & Tsimberidou, A. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1001734 · Cited by 23

The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs

Arra, A., Lingel, H., Kuropka, B., Pick, J., Schnoeder, T. M., Fischer, T., Freund, C., Pierau, M., & Brunner-Weinzierl, M. C. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1273300 · Cited by 23

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors

Franzese, O., Torino, F., Fuggetta, M. P., Aquino, A., Roselli, M., Bonmassar, E., Giuliani, A., & D’Atri, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16335 · Cited by 23

Research progress in tumor targeted immunotherapy

Fang, Y., Yu, A., Ye, L., & Zhai, G. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1882992 · Cited by 23

Network Medicine‐Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD‐L1 Expression via Targeting SPOP in Cancer

Tian, S., Xu, M., Geng, X., Fang, J., Xu, H., Xue, X., Hu, H., Zhang, Q., Yu, D., Guo, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202410285 · Cited by 22

Immune checkpoint inhibitors for hepatocellular carcinoma

Jensen, C. E., Loaiza‐Bonilla, A., & Bonilla-Reyes, P. A. (2016) · Hepatic Oncology · doi:10.2217/hep-2016-0004 · Cited by 22

Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy

Patel, K. J., Siraj, S., Smith, C., Nair, M. P., Vishwanatha, J. K., & Basha, R. M. (2019) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2019031417 · Cited by 22

Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors

Zhu, N., Weng, S., Wang, J., Chen, J., Yu, L., Fang, X., & Yuan, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03044-5 · Cited by 22

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions

Donini, M., Buti, S., Massari, F., Mollica, V., Rizzo, A., Montironi, R., Bersanelli, M., & Santoni, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1770601 · Cited by 21

Gut Commensal Segmented Filamentous Bacteria Fine-Tune T Follicular Regulatory Cells to Modify the Severity of Systemic Autoimmune Arthritis

Bates, N. A., Li, A., Fan, T., Cutcliffe, M. P., Dagenet, C. B., Sleiman, K. C., Ma, H., Tahsin, S., Garrett, C. S., Altemus, J. J., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000663 · Cited by 22

Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis

Luu, K., Patwardhan, M. V., Zeng, Q., Wickström, S. L., Lundqvist, A., & Schwarz, H. (2021) · Cells · doi:10.3390/cells10020353 · Cited by 28

Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection

Awadasseid, A., Yin, Q., Wu, Y., & Zhang, W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111957 · Cited by 24

Structural and functional insights into the modulation of T cell costimulation by monkeypox virus protein M2

Yang, S., Wang, Y., Yu, F., Cheng, R., Zhang, Y., Zhou, D., Ren, X., Deng, Z., & Zhao, H. (2023) · Nature Communications · doi:10.1038/s41467-023-40748-2 · Cited by 22

Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)

Hu, X., Ren, J., Xue, Q., Luan, R., Ding, D., Tan, J., Su, X., & Yang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5570 · Cited by 22

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment

Luo, H., Wang, W., Mai, J., Yin, R., Cai, X., & Li, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267918 · Cited by 22

Phosphatidylserine externalization as immune checkpoint in cancer

Kur, I.-M., & Weigert, A. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-02948-7 · Cited by 21

Immune checkpoint inhibition in lymphoid disease

Eyre, T. A., & Collins, G. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13397 · Cited by 22

Recent advances in cancer immunology and immunology-based anticancer therapies

Kumar, S., Saini, R. V., & Mahindroo, N. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.126 · Cited by 21

CD4+ Foxp3+ regulatory T cell-mediated immunomodulation by anti-depressants inhibiting acid sphingomyelinase

Schneider‐Schaulies, J., & Beyersdorf, N. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0159 · Cited by 21

Two Strikes and You’re Out? The Pathogenic Interplay of Coinhibitor Deficiency and Lymphopenia-Induced Proliferation

Ellestad, K. K., & Anderson, C. C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601884 · Cited by 22

Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer

Dehno, M. N., Li, Y., Weiher, H., & Schmidt‐Wolf, I. G. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093078 · Cited by 22

Immunostimulatory biomaterials to boost tumor immunogenicity

Shofolawe-Bakare, O. T., Stokes, L. D., Hossain, M., Smith, A. E., & Werfel, T. A. (2020) · Biomaterials Science · doi:10.1039/d0bm01183e · Cited by 24

A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding

Douthwaite, J. A., Moisan, J., Privezentzev, C. V., Soskic, B., Sabbah, S., Cohen, E. S., Collinson, A., England, E., Huntington, C., Kemp, B., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600682 · Cited by 22

Treatment strategies and molecular mechanism of radiotherapy combined with immunotherapy in colorectal cancer

Jin, Y., Jiang, J. F., Mao, W. B., Bai, M., Chen, Q., & Zhu, J. Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216858 · Cited by 24

Checkpoint inhibitors in immunotherapy of ovarian cancer

Wang, D., Guo, L., & Wu, X.-H. (2014) · Tumor Biology · doi:10.1007/s13277-014-2848-2 · Cited by 21

Induced Treg Cells Augment the Th17-Mediated Intestinal Inflammatory Response in a CTLA4-Dependent Manner

Watanabe, N., Kaminuma, O., Kitamura, N., & Hiroi, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150244 · Cited by 21

An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis

So, A., & Inman, R. D. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.12.002 · Cited by 21

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

Hurkmans, D. P., Verdegaal, E. M. E., Hogan, S. A., de Wijn, R., Hovestad, L., van den Heuvel, D. M. A., Ruijtenbeek, R., Welters, M. J. P., van Brakel, M., Basak, E. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001607 · Cited by 20

Costimulation blockade and Tregs in solid organ transplantation

Muckenhuber, M., Wekerle, T., & Schwarz, C. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.969633 · Cited by 21

Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity

Wang, C. J., Petersone, L., Edner, N. M., Heuts, F. W. H., Ovcinnikovs, V., Ntavli, E., Kogimtzis, A., Fabri, A., Elfaki, Y., Houghton, L. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34477-1 · Cited by 21

Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80

Kang-Pettinger, T., Walker, K., Brown, R., Cowan, R. H., Wright, H., Baravalle, R., Waters, L. C., Muskett, F. W., Bowler, M. W., Sawmynaden, K., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102769 · Cited by 21

Modulation of T cell function and survival by the tumor microenvironment

Mani, N. L., Andrews, D., & Obeng, R. C. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1191774 · Cited by 22

Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC)

Mousa, A. M., Enk, A. H., Hassel, J. C., & Reschke, R. (2024) · Cells · doi:10.3390/cells13191615 · Cited by 24

Immunogenetic Mechanisms Leading to Thyroid Autoimmunity: Recent Advances in Identifying Susceptibility Genes and Regions

Brand, O., & Gough, S. (2011) · Current Genomics · doi:10.2174/138920211798120790 · Cited by 25

EphB4 Promotes Osteogenesis of CTLA4-Modified Bone Marrow-Derived Mesenchymal Stem Cells Through Cross Talk with Wnt Pathway in Xenotransplantation

Zhang, F., Zhang, Z., Sun, D., Dong, S., Xu, J., & Dai, F. (2015) · Tissue Engineering Part A · doi:10.1089/ten.tea.2015.0012 · Cited by 21

Interference of the T Cell and Antigen-Presenting Cell Costimulatory Pathway Using CTLA4-Ig (Abatacept) Prevents Staphylococcal Enterotoxin B Pathology

Whitfield, S. J., Taylor, C., Risdall, J. E., Griffiths, G. D., Jones, J. T. A., Williamson, E. D., Rijpkema, S. G. T., Saraiva, L., Vessillier, S., Green, A. C., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601525 · Cited by 21

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody

Gombos, R. B., Gonzalez, A., Manrique, M. L., Chand, D. S., Savitsky, D. A., Morin, B. M., Breous-Nystrom, E., Dupont, C. D., Ward, R., Mundt, C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191926 · Cited by 21

Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules

D’Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., Romano, M. F., & Romano, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181106114421 · Cited by 21

Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus

Taylor, E. B., Sasser, J. M., Maeda, K., & Ryan, M. J. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00616.2018 · Cited by 22

Approaches to inducing antigen‐specific immune tolerance in allergy and autoimmunity: Focus on antigen‐presenting cells and extracellular vesicles

Nazimek, K., & Bryniarski, K. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12881 · Cited by 21

Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations

Niedbała, M., Malarz, K., Sharma, G., Krämer-Marek, G., & Kaspera, W. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s215997 · Cited by 22

Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence

Eshaq, A. M., Flanagan, T. W., Abbad, A. A. B., Makarem, Z. A. A., Bokir, M. S., Alasheq, A. K., Asheikh, S. A. A., Almashhor, A. M., Binyamani, F., Al-Amoudi, W. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010088 · Cited by 23

Nanoneedle‐Based Electroporation for Efficient Manufacturing of Human Primary Chimeric Antigen Receptor Regulatory T‐Cells

Sun, N., Wang, C., Edwards, W., Wang, Y., Lü, X., Gu, C., McLennan, S., Shangaris, P., Peng, Q., Mastronicola, D., et al. (2025) · Advanced Science · doi:10.1002/advs.202416066 · Cited by 22

Hyperglycemia induces an immunosuppressive microenvironment in colorectal cancer liver metastases by recruiting peripheral blood monocytes through the CCL3-CCR1 axis

Peng, H., Pan, Y., Sun, Y., Wang, X., Fan, X., Wang, Y., Zhao, L., Li, X., Yan, D., Chen, J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011310 · Cited by 20

Regulatory T Cells in the Immunodiagnosis and Outcome of Kidney Allograft Rejection

Franzese, O., Mascali, A., Capria, A., Castagnola, V., Paganizza, L., & Daniele, N. D. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/852395 · Cited by 20

T Helper Cells Fate Mapping by Co-stimulatory Molecules and its Functions in Allograft Rejection and Tolerance.

Abdoli, R., & Najafian, N. (2014) · International Journal of Organ Transplantation Medicine · Cited by 19

A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope

Li, D., Li, J., Chu, H., & Wang, Z. (2020) · mAbs · doi:10.1080/19420862.2020.1725365 · Cited by 20

Dysfunctions, Molecular Mechanisms, and Therapeutic Strategies of Regulatory T Cells in Rheumatoid Arthritis

Li, X., Xu, H., Huang, J., Luo, D., Lv, S., Lu, X., & Xiao, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.716081 · Cited by 20

Trogocytosis in innate immunity to cancer is an intimate relationship with unexpected outcomes

Mattei, F., Andreone, S., Spadaro, F., Noto, F., Tinari, A., Falchi, M., Piconese, S., Afferni, C., & Schiavoni, G. (2022) · iScience · doi:10.1016/j.isci.2022.105110 · Cited by 22

CD8+ T Cell Phenotype and Function in Childhood and Adult-Onset Connective Tissue Disease

Radziszewska, A., Moulder, Z., Jury, E. C., & Ciurtin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911431 · Cited by 20

TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways

Chan, W., Cao, Y. M., Zhao, X., Schrom, E. C., Jia, D., Song, J., Sibener, L. V., Dong, S., Fernandes, R. A., Bradfield, C. J., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20231242 · Cited by 21

Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment

Chaudhri, A., Lizee, G. A., Hwu, P., & Rai, K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2244 · Cited by 21

Cellular and molecular signaling towards T cell immunological self-tolerance

Carbone, F., Russo, C., Colamatteo, A., Rocca, C. L., Fusco, C., Matarese, A., Procaccini, C., & Matarese, G. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107134 · Cited by 22

Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions

Sharma, S., Singh, N., Turk, A. A., Wan, I., Guttikonda, A., Dong, J. L., Zhang, X., & Opyrchal, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i13.1815 · Cited by 22

Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer

Jama, M., Tabana, Y., & Barakat, K. (2024) · European journal of medical research · doi:10.1186/s40001-024-01901-9 · Cited by 20

The Endocytosis and Signaling of the γδ T Cell Coreceptor WC1 Are Regulated by a Dileucine Motif

Hsu, H., Baldwin, C. L., & Telfer, J. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402020 · Cited by 20

Common Gamma Chain Cytokines Promote Rapid In Vitro Expansion of Allo-Specific Human CD8+ Suppressor T Cells

Yu, Y., Zitzner, J. R., Houlihan, J. L., Herrera, N. D., Xu, L., Miller, J. W., Mathew, J. M., Tambur, A. R., & Luo, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028948 · Cited by 20

In Vivo Expansion of Endogenous Regulatory T Cell Populations Induces Long-Term Suppression of Contact Hypersensitivity

Beidaq, A. E., Link, C. W. M., Hofmann, K., Frehse, B., Hartmann, K., Bieber, K., Martin, S. F., Ludwig, R. J., & Manz, R. A. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600508 · Cited by 20

Role of TRAFs in Signaling Pathways Controlling T Follicular Helper Cell Differentiation and T Cell-Dependent Antibody Responses

Pedros, C., Altman, A., & Kong, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02412 · Cited by 21

Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors

Davar, D., & Zarour, H. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_2 · Cited by 20

Force-dependent trans-endocytosis by breast cancer cells depletes costimulatory receptor CD80 and attenuates T cell activation

Park, S., Shi, Y., Kim, B. C., Jo, M. H., Cruz, L. O., Gou, Z., Ha, T., Lu, L., Reich, D. H., & Chen, Y. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112389 · Cited by 20

Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1

Mathew, D., & Torres, R. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.531910 · Cited by 22

Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update

Obi, O. N., Lower, E. E., & Baughman, R. P. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1878024 · Cited by 20

Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer

Aoki, H., Ueha, S., Shichino, S., Ogiwara, H., Shitara, K., Shimomura, M., Suzuki, T., Nakatsura, T., Yamashita, M., Kitano, S., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0989 · Cited by 20

Circulating Regulatory T Cells Expressing Tumor Necrosis Factor Receptor Type 2 Contribute to Sepsis-Induced Immunosuppression in Patients During Septic Shock

Gaborit, B. J., Chaumette, T., Chauveau, M., Asquier-Khati, A., Roquilly, A., Boutoille, D., Josien, R., Salomon, B. L., & Asehnoune, K. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab276 · Cited by 20

Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells

Heinrich, B., Goepfert, K., Delic, M., Galle, P. R., & Möhler, M. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s49371 · Cited by 20

Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events?

Riondino, S., Rosenfeld, R., Formica, V., Morelli, C., Parisi, G., Torino, F., Mariotti, S., & Roselli, M. (2024) · Cancers · doi:10.3390/cancers16071251 · Cited by 20

Immunotherapy for lung cancer: for whom the bell tolls?

Madureira, P., de Mello, R. A., de Vasconcelos, A., & Zhang, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-3285-6 · Cited by 19

The Phenotypic Markers of CD4+CD25+ T Regulatory Lymphocytes

Lašťovička, J. (2013) · Research in Endocrinology · doi:10.5171/2013.119348 · Cited by 18

Whole-genome resequencing analysis of Pengxian Yellow Chicken to identify genome-wide SNPs and signatures of selection

Yin, H., Li, D., Wang, Y., & Zhu, Q. C. (2019) · 3 Biotech · doi:10.1007/s13205-019-1902-6 · Cited by 19

The Effect of Talaromyces marneffei Infection on CD86 Expression in THP-1 Cells

Yang, D., Shen, L., Chen, R., Fu, Y., Zhang, L., Xu, H., & Liu, D. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s297160 · Cited by 19

Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma

Vanella, V., Festino, L., Vitale, M. G., Alfano, B., & Ascierto, P. A. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1901884 · Cited by 19

Clinical and diagnostic potential of regulatory T cell markers: From bench to bedside

Haddadi, M. H., & Negahdari, B. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101518 · Cited by 20

Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation

Panda, A. K., Kim, Y.-H., & Shevach, E. M. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100653 · Cited by 19

Moving to the Outskirts: Interplay Between Regulatory T Cells and Peripheral Tissues

Brull, A. E., Panetti, C., & Joller, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864628 · Cited by 20

RORγt+Foxp3+ regulatory T cells in the regulation of autoimmune arthritis

Furuyama, K., Kondo, Y., Shimizu, M., Yokosawa, M., Segawa, S., Iizuka, A., Tanimura, R., Tsuboi, H., Matsumoto, I., & Sumida, T. (2021) · Clinical & Experimental Immunology · doi:10.1093/cei/uxab007 · Cited by 19

New‐onset type 1 diabetes and severe acute respiratory syndrome coronavirus 2 infection

Anindya, R., Rutter, G. A., & Meur, G. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12615 · Cited by 20

CTLA-4-mediated trans-endocytosis in the control of T cell co-stimulation

Ovcinnikovs, V. (2018) · UCL Discovery (University College London)

Investigating transendocytosis mediated by CTLA4

Nguyen, L. (2023) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/24962

CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis

Xu, X., Dennett, P., Zhang, J., Sherrard, A., Zhao, Y., Masubuchi, T., Bui, J. D., Chen, X., & Hui, E. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221391 · Cited by 56

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation

Kennedy, A., Waters, E., Rowshanravan, B., Hinze, C., Williams, C., Janman, D., Fox, T. A., Booth, C., Pesenacker, A. M., Halliday, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01289-w · Cited by 227

Molecular and Cellular Functions of CTLA-4

Coillie, S. V., Wiernicki, B., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 259